Literature DB >> 1973106

The effect of medetomidine, an alpha 2-adrenoceptor agonist, in various pain tests.

A Pertovaara1, T Kauppila, T Tukeva.   

Abstract

Medetomidine, a new alpha 2-adrenoceptor agonist produced dose-dependent (30-100 micrograms/kg i.p.) analgesia in the formalin test in rats, and this effect was reversed by atipamezole (1 mg/kg), a new alpha 2-adrenoceptor antagonist. However, medetomidine at the dose of 100 micrograms/kg did not influence tail flick latencies or latencies of the biting response to mechanical pinch stimuli. Moreover, medetomidine produced sedation and a decrease in locomotor activity. In comparison, the non-sedative monoaminergic agent, cocaine (25 mg/kg), produced highly significant analgesic effects in the formalin and mechanical pain tests. The cocaine effect in the formalin test was not reversed by atipamezole (1 mg/kg). It is concluded that the analgesic effect of medetomidine in the formalin test is due to supraspinal mechanisms related to sedation and is mediated by alpha 2-adrenoceptors. The alpha 2-adrenoceptors are not involved in cocaine-induced anagesia.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1973106     DOI: 10.1016/0014-2999(90)90172-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

Review 1.  Janus molecule I: dichotomous effects of COMT in neuropathic vs nociceptive pain modalities.

Authors:  S K Segall; W Maixner; I Belfer; T Wiltshire; Z Seltzer; L Diatchenko
Journal:  CNS Neurol Disord Drug Targets       Date:  2012-05       Impact factor: 4.388

2.  Anxiety- and activity-related effects of paracetamol on healthy and neuropathic rats.

Authors:  Zuyue Chen; Hong Wei; Antti Pertovaara; Jianhong Wang; Synnöve Carlson
Journal:  Pharmacol Res Perspect       Date:  2018-02

3.  Low-molecular synthetic peptides with non-narcotic type of analgesia: comparative study and mechanism of analgesic activity.

Authors:  Arkady M Kotin; Maksim O Emelyanov; Oleg A Kotin
Journal:  Mol Pain       Date:  2019 Jan-Dec       Impact factor: 3.395

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.